• Guilherme Fleury Perini, Thais Fischer, Rafael Dezen Gaiolla, Talita Bueno Rocha, Marcelo Bellesso, Larissa Lane Cardoso Teixeira, Marcia Torresan Delamain, Adriana Alves de Souza Scheliga, Glaciano Nogueira Ribeiro, Jorge Vaz Neto, Otávio Cesar Carvalho Guimaraes Baiocchi, André Neder Ramires Abdo, Celso Arrais-Rodrigues, Laura M Fogliatto, Ricardo de Sá Bigni, Rony Schaffel, Irene Biasoli, Juliana Pereira, Samir Kanaan Nabhan, Cármino Antônio de Souza, Carlos Sérgio Chiattone, and Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH).
• Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Américas Oncologia, São Paulo, SP, Brazil. Electronic address: guilherme.perini@einstein.br.
• Hematol Transfus Cell Ther. 2020 Apr 1; 42 (2): 103-110.

AbstractThe novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.Copyright © 2020. Published by Elsevier Editora Ltda.

6 keywords...

hide…